Plenty of studies [39] also pointed out that Afatinib is an irreversible ErbB family blocker, targeting oncogenes such as EGFR, ERBB2 and ERBB3 (that are also included in the oncogene subcomponent of the two cell lines), and is widely used in the treatment of lung cancer. This evidence concerns the gene ERBB2 and lung cancer.